U-Neuron Biomedical (6973.TWO) Stock Price

U-Neuron Biomedical Price

CLOSED
50.20
​
Market closed

Over the last 3 years U-Neuron Biomedical grew revenue by 17.6% annually, reaching 46.21 M TWD. For U-Neuron Biomedical, the net margin of -129.8% is down versus -39.6% a few years ago.

U-Neuron Biomedical stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

U-Neuron Biomedical business model & stock analysis

U-Neuron Biomedical Inc develops cosmetics, health care consumer products, and new drugs using allogeneic amniotic fluid stem cells and their derivatives. The company's new drug portfolio includes UA002 for erectile dysfunction and UB003 for dry eye, while its cosmetic line features masks, essences, and creams for anti-aging, repairing, and moisturizing. These products are primarily sold within Taiwan, targeting domestic consumers seeking medical beauty and health care solutions. The company leverages the regenerative properties of amniotic fluid stem cells to create applications in both therapeutic and cosmetic segments. The business model focuses on developing products around deer amniotic fluid stem cell derivatives for cosmetics, which form the core of its health care consumer product line. UA002 and UB003 represent the company's pharmaceutical offerings, addressing specific medical conditions with stem cell-based treatments. Domestic sales drive revenue, with no mention of international markets or additional distribution channels in the provided description. U-Neuron Biomedical Inc's revenue streams come from the domestic sale of its cosmetic products and pharmaceuticals. The company's product segments are clearly divided between new drug development and cosmetic/health care consumer products, with each segment utilizing stem cell technology in different applications. Sales are concentrated within Taiwan, where the company's products meet local demand for regenerative medicine and beauty solutions.

Frequently asked questions about U-Neuron Biomedical

Converted at the current exchange rate, the U-Neuron Biomedical share trades at 1.39 EUR (50.20 TWD).

The revenue cannot currently be calculated for U-Neuron Biomedical.

The profit cannot currently be calculated for U-Neuron Biomedical.

The P/E ratio cannot be calculated for U-Neuron Biomedical at the moment.

The P/S cannot be calculated for U-Neuron Biomedical currently.

The Eulerpool Quality Score for U-Neuron Biomedical is 5/10.

The ISIN of U-Neuron Biomedical is TW0006973001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of U-Neuron Biomedical is 6973.TWO. The ticker symbol is used to trade U-Neuron Biomedical shares on the stock exchange.

Fair ValueTerminal
46.18 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website u-neuron.com
Country
Taiwan
Currency
TWD
Initial public offering
Jul 20, 2023
ISIN
TW0006973001
Cusip
Y90481105
Market capitalization
1.99 B TWDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
2.45
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-7.35 %
Last updated Nov 22, 2026, 3:45 AM

U-Neuron Biomedical Peer Group

U-Neuron Biomedical FIGI

6973:TT (Taipei Stock Exchange) · BBG01HDNB8S6